Gastroenterology Research and Practice

Clinical Study

Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C

Table 3

Results of multivariate stepwise analysis for associated factor to SVR.


Factor	Category	Patients with SVR, no./total (%)	Patients without SVR, no./total (%)	P value	95% CI

Gender
	Male	98/145 (67.6)	47/145 (33.4)	0.114	1.23 (0.91–2.03)
	Female	67/98 (68.4)	31/98 (31.6)	0.114	1.23 (0.91–2.03)
Age
	<40 years	93/132 (70.5)	39/132 (29.5)	0.093	1.02 (0.83–1.72)
	≥40 years	74/111 (66.7)	37/111 (33.3)	0.093	1.02 (0.83–1.72)
HCV genotype
	Genotype 1	73/130 (56.2)	57/130 (43.8)	0.0002	3.87 (2.16–5.89)
	Genotype 2/3/6	92/113 (81.4)	21/113 (18.6)	0.0002	3.87 (2.16–5.89)
Absence of cirrhosis
	With	35/66 (53.0)	31/66 (47.0)	0.008	2.47 (1.36–3.67)
	Without	130/177 (73.4)	47/177 (26.5)	0.008	2.47 (1.36–3.67)
HCV RNA level
	<600 IU/mL × 10³	87/118 (73.7)	31/118 (26.3)	0.038	1.68 (1.12–2.57)
	≥600 IU/mL × 10³	78/125 (62.4)	47/125 (37.6)	0.038	1.68 (1.12–2.57)
Peg-IFN α-2a dose
	90 μg/week	62/93 (66.7)	31/93 (33.3)	0.106	1.31 (0.94–1.81)
	180 and135 μg/week	103/150 (68.7)	47/150 (31.3)	0.106	1.31 (0.94–1.81)

Notes. OR: odds ratio; CI: confidence interval. The association was analyzed by multivariate stepwise analysis included in the model the following preselected variables: peg-IFN α-2a dose of treatment (lower dose versus standard dose), gender (male versus female), age (aged < 40 years versus ≥ 40 years), HCV genotype (genotype 1 versus 2/3/6), absence of cirrhosis(with versus without), and HCV RNA level (<600 IU/mL × 10³ versus ≥600 IU/mL × 10³).